Home AboutCriteriaPortfolioTeamContact
HomeAffiliatesNewsSite Map
 
   

Hunt BioVentures
Hunt Energy Enterprises
Hunt Investment Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acorda (NASDAQ: ACOR)

Acorda develops therapeutic products for spinal cord injury and other central nervous system disorders.
(IPO February 2006)
www.acorda.com

 
 

 

Anesiva (NASDAQ: ANSV)

Anesiva develops innovative drugs for the treatment of acute and chronic pain.
(Originally AlgoRx, merger w/ Corgentech in December 2005.)
www.anesiva.com

 
 

 

Athenix

Athenix develops and commercializes high-value genetic traits from microbes for use in agricultural products.
(Acquired by Bayer Crop Sciences in November 2009.)
www.athenixcorp.com

 

 
 

 

Avalon

Avalon discovers and develops novel drugs for various cancers. (Merged w/ Clinical Data Inc in May '09 – NSDQ:CLDA)
www.avalonrx.com

 

 
   

BioMs (TSX: MS)

BioMs develops unique biologics for autoimmune diseases with a special emphasis on multiple sclerosis.
www.biomsmedical.com

 

 
 

 

 

InteKrin

InteKrin Therapeutics in-licenses and develops drugs for the treatment of various metabolic diseases.
www.intekrin.com


 
 

 

 

IntelliDx

IntelliDx is developing an automated, bedside blood analyzer for use in the critical care areas of hospitals.
www.intellidx.com


 
   

MacroGenics

MacroGenics is focused on the development of improved immunotherapeutic products and the identification of new targets for the treatment of cancer, autoimmune disorders, allergy, or infectious diseases.
www.macrogenics.com

 

 
   

Morphotek

Morphotek develops therapeutic monoclonal antibodies for the treatment of cancer, inflammatory and infectious diseases. (Acquired by Eisai Pharmaceuticals in April 2007.)
www.morphotek.com

 

 
   

Myogen

Myogen is engaged in the discovery and development of drugs for the treatment of heart failure and related cardiovascular conditions.
(IPO 2003; acquired by Gilead Sciences in 2006.)
www.myogen.com

 

 
   

Novelos (OTC BB: NVLT)

Novelos develops oxidized glutathione-based drugs for the treatment of cancer and hepatitis.
www.novelos.com

 

 
   

Peptimmune

Peptimmune develops drugs for the treatment of various autoimmune diseases.
www.peptimmune.com

 

 
   

Salmedix

Salmedix develops oncology drugs with an initial emphasis on hematologic cancers.
(Acquired by Cephalon in 2005.)
www.cephalon.com

 

 
   

Sirtris

Sirtris develops novel treatments for metabolic disease with a focus on sirtuin enzymology. (IPO 2007; acquired by GSK in April 2008.)
www.sirtrispharma.com


 
   

Synageva

Synageva develops novel, next-generation and follow-on protein therapeutics that leverage the unique competitive advantages of its expression platform.
www.synageva.com

 

 
 

©2009 Hunt BioVentures All Rights Reserved
| Legal Notice | About | Criteria | Portfolio | Team | Contact | Affiliates | News | Site Map |